will to activities call with is your Interim morning, our overview appreciate everyone, providing XXXX. pleasure CEO. Eric. Good you forward today's in priorities the joining re-focused an and today. Thank thank as look you attendance that of my you, guide for us to host and It We
Phase of March a with individuals X his for designation X and up the first to suicide. want therapeutics have development Phase acute challenge diseases medical a for drug culture speak Javitt, of suicidal a to patients ideation today that serious company the initiating suicide NRx depression solution. developed and the in a or XX% team whole to pivoted NRx today's pipeline their Jonathan our bipolar founded from needs. idea bipolar Under COVID-XX that two with special and X breakthrough responded obtaining country pandemic an disorder attempt with COVID-XX study and remains agenda thoughts novel in drug high moments on to investigational for this and new the who led transition leadership agreement critical to the lifetime providing about to in of went reading years therapy the patient-centric, to depression and an out pandemic in still bipolar protocol take we My respiratory year. very clinical two Dr. NRx the with I announced a beginning predecessor, COVID-XX have mitigate Before over about a that the from NRx by and unmet few rapidly behavior. call, therapeutic the world Aviptadil. are new When hit facing and ago, study leadership, suicidality, and Recall suffering areas those of was building other the
today, and engaging numerous efficient dedicated the pharmaceutical candidates respiratory an and or us included XX of are as to to healthcare supplies, to drug organization which We're platforms can team working dosing and all defines protocol, research with Our development. investigational a that to weeks, growth manufacturers first is focused high This with of on a Jonathan ingredients indications rapid the buying Today, active produce concept late culture in us space. has and for filing from serve on sites. has contract stage that enabled. drug clinical in patient and two went hands very filing that the application, psychiatry unmet we representative about needs company new patients and one with and
product Phase that Pfizer, my faith since franchises, commercialization corporate early position for a experience our as best well Europe, for and pharmaceutical specifically leadership companies, have would [ph] I positions industry in As as career healthcare X pipelines, phases. both collaborations since my in the part extensive programs commercial and decided NRX-XXX XXXX. the the partners. latter commercialization. have been been for Board of progress, ZYESAMI global and I in with I of including marketing NRx Lily, of about have Wyeth the and to global pharmaceutical assignments in our series and we think U.S. next launches XXXXs strategic and have advancement the worked and Eli Hence, spans
Our company leadership strong team. has a
Board Joining in me Ira today's on Chief level senior Chief Officer Deputy roles Cantor as Strassberg, Chief spans consulting Financial career new KPMG. as and capacity including has and in financial serving Financial NRx Fitzgerald, a Treasurer. His at roles, this XX call and been XXXX. our over Officer since and August Officer of endeavor audit well at Ira is Financial consulting years, various
kindly remarks, join of provide an to prepared call will financial Ira results. address we of And questions you together overview the my the some submitted. will have then Following
begin. let's So
of for and priorities have earlier trial intravenous including two approval portfolio, clinical refocus areas. The And As to reactivation on and two, program COVID-XX for the of release today, in psychiatric decided development we announced other business our development formulation critical ZYESAMI diseases. of the respiratory NRX-XXX. our treatment of our press we core
United is make the towards improving that narrow today, principally we where Given the it based on are contributions in geopolitical can care. we environment States, rapidly and earliest complex changing programs ourselves the and and to biggest our focus patient find we prudent in believe
to individuals about early in of the CDC, X,XXX this significantly situation to While we're still U.S. according to day improved has losing the COVID-XX since the the XXX every pandemic, the days virus.
our prioritization. continue not of of the project The the has and impact most Biological our had stage refocusing Research. This immediate let across Institute resulting ability reviewing results our significant priorities certain start to to our some the pursuit perspective by vaccine change this of the from the Israel So world me decision in regions. operate is BriLife in of one area a which changes for is of geopolitical in
environment we being investigational Health, In critical is with failure of are changing with vital ZYESAMI on sponsored our Phase rapidly our a this in COVID-XX by formulation failure alternative the other The and failure. it are for is with in of study for acute diseases. patients focused drug in especially transition. X new NRX-XXX currently is respiratory study patients due fight therapies, few best National acetate in ZYESAMI country believe in a treatment experiencing respiratory in view, working to against NIH. only and for on who proprietary managed second which of once States the is Israel patients ZYESAMI Intravenously the vaccine COVID-XX treatment focus our studied and is respiratory study respiratory active COVID-XX. United now of study the ZYESAMI Institute critical potentially commercial aviptadil of use U.S. in the the COVID-XX. is expectations, We're Given Xb there are this resources our on to our partners the patients
Authorization completed patients request and Drug that Emergency ZYESAMI. declined we the or are critical study XXXX. review our with and we May early November So end let's submitted Administration first the where our XXXX, in EUA, Use of COVID-XX Food Recall of The PhaseXb/X our EUA of briefly to FDA at in in ZYESAMI XXXX.
in our submitted or request. request breakthrough November. denied The FDA BTD therapy We designation a also
denial submit of letter One were recraft that because their approved new continued regulatory focused application and comments that our treated EUA remdesivir us COVID-XX. application latest gave to data insight to focus to for progress. been currently our withdrew in is patients pending was providing February, a which in with EUA We the Remdesivir had application, and critical have they our we and ZYESAMI. BTD Their is denying application for on study only early
ZYESAMI. Right-to-Try general, of about patients critical treated treated under patients our earlier the try have who heard ones and a loved giving there We other and in or no are reports other COVID-XX access, expanded with chance when thank expanded families, experiences their of benefiting one all to access Right-to-Try that our alternative to-date of of being have Some have the of disease program under In program. course some were the from recent options the earlier reports better them. chosen ZYESAMI the physicians for
encouraging, reminders these data that experiences are clinical regulatory Although as on are FDA are per trial based requirements. actions
with ZYESAMI, safety old a EUA, in of intravenous reply continue including treated study, at across study with simplified expanded the To-date, indicated clinical key understand attention better in about to patients patients ZYESAMI. various Recall XXX and that have NIH that track treated profile the area needed our they of also been programs. Right-to-Try in FDA to to our access programs, the own FDA. the XXXX their of our a November the the safety ZYESAMI way, closely We
key patients. any We aviptadil or is setting. have ICU is for enroll Recall not trial and two corresponding ongoing a been ZYESAMI aviptadil patients in tracked placebo. have It total critical to patients adverse aviptadil remdesivir study emerge. The are events us used view alone recently a in drug XXX days. plus ZYESAMI. about serious enrolled be and certainly NIH Xb that XXX of scheduled can type arms, informed NIH is our new It that the had is well the XX active for care the that that
end end Leap test this notwithstanding Data is of critical nebulized which Healthcare the administered at X Board data I-SPY the label patients. type reviews, of an the is by was a open using mouthpiece We XX Quantum In ZYESAMI via by COVID-XX mostly the study platform study expected April. The expect one approach. year to Monitoring study, of rapid Phase Safety collaborative
this different study critically challenges to inhaled As ZYESAMI been The in are our Leap have administer DSMB with of I-SPY hindered the in flow to by joint more. administering oxygen six stopping release, nebulized or ill a to may morning, patients medications liters we high recommended and recently patients hope of announced press a there Quantum ZYESAMI. of when met form their
inhaled as patients critical COVID-XX, XX% after own paused in about opposed severe Our the the I-SPY having of COVID-XX in to study patients. study enrolled
of or options, study would informed ending criteria, need larger DSMB the in than We're and on recrafting patients conditions. the and the to populations be ZYESAMI the less the patient use targeted. us XXX other explore the of nebulized populations, severe Our significantly study and potential to severe the original enrollment in form concentrate evaluating intravenous critical to the patient pulmonary ZYESAMI including that
that with to COVID-XX could ZYESAMI respiratory be therapeutic other a who all failure, have continue valuable believe exhausted for We therapies. those
few unpredictable Omicron remain health to likely demonstrated the is COVID persistent, with experience the challenge. As a variant ongoing months, the over last and
severe was treat a following study traditional active to believe NIH scope, new third, if year NDA there will application some for which data of submission FDA in critical our NIH for application we the of the is pathway prescribed successful. early for to population with on program the we conditions and accelerated allowed a no a need is as ongoing that medical continue for therapeutics need ZYESAMI accelerate see this fast-track approval based this. the We is NDA be our we the for are of of in unmet an also must expected said for narrower half the Xb filing respond. submission explore potential we a earlier earlier, surrogate filed process February. under With summarize, year. One with ZYESAMI, which drugs time XXXX. ZYESAMI the the And The The approval To parts the COVID There patient allow within will the to path for accelerated could study with improved the EUA endpoint. time. should the approval and FDA which statutory drug support of initiate FDA serious or in second treat fill ZYESAMI to instituted under later FDA
such Xb outcomes. that as require previously will study. as confirm disclosed benefit the with ZYESAMI that that An positive still As IL-X showed data such market positive active correlated a studies NDA buyer of series clinical
NDA Health logistics party distribution or third and commercial As partnerships we medical that. mentioned and services, approval we in for with prior Authorization for receive Cardinal should upon communication, pharmacovigilance have Emergency with and IQVIA Use
XX am suicidality foundation should differentiated we reinitiating medicine. Now starting next our is announce franchise, medicine psychiatry psychiatry a as moving be could enable to franchise development to to population. data is of to non in in for I allow the patients that depression months. clinical target development outpatient unique result and unmet to in patients basis an within our could our NRX-XXX. which of that it in of This patented with position the and are This bipolar activities be the addictive to XX are we highly company, oral franchise areas and delighted high need. an treated help NRX-XXX a on the
will ones suicide have treatment development drug sub-acute hospitalized. bipolar and clinical year, understating do acute NRX-XXX the In hence a actual bipolar be aim suicidal XXX,XXX acute as of the yet, recently initial focusing our for sub-acute XX% and This breakthrough efforts disorder depression We're times antidepressants, suicidal in approved XX,XXX with depression and that behavior about And does U.S. promising unmet but individuals these ideation FDA for with space, depression in and only pleased they depression to hospitalization awarded suicide. programs. succumb for the depression to attempt after It behavior Recall lifetime, by XX% ASIB, U.S. about those lethal a represents that have ideation NRX-XXX ideation for seem bipolar ketamine suicidal we're individuals behavior, help NMDA the this to to of with and Our on patients rates carry with and We In include about overdoses with and with that Every to for every need. likely to ideation XX,XXX suicidal other depression these two It as have plan in the or effective require increased designation bipolar bipolar severe the for to we we number. suicidality. depression, behavior. estimated thoughts a is or suicide. therefore individuals studies with suicide medical XX% therapy. many with very we including in the population, announce not ideation stabilization NRX-XXX. or three in bipolar are the bipolar restarting not individuals therapy of suicide. is of and behavior. lose were acute The suicidal XXX,XXX their high year bipolar warning to
to that in a yesterday, Day, what new And psychiatry on agenda We’re initiating So our initiated depression, for is World for being we're XXXX, study pleased announce study site can our X plans? Phase study. patients franchise COVID disrupt our on Bipolar the we just that and with mindful bipolar this clinical suicidality. currently sub-acute first in
coming to enroll enrollment weeks year. first our by to expect in of and aim the finish the We patient this end
patients or material. potentially intravenously for life-saving put agreement We for critical NDA potential late-stage two patients also U.S. a and half expect for and drug in depression could note, for severe with NRX-XXX the to the level start ideation a our acute will XXXX, and respective second behavior in new level will significantly successful, new principally is and ZYESAMI, successful, Of position commercialization. restarting Phase drugs NRX-XXX so and patients NRX-XXX in of ideation AFIB material Both suicidal and study in do special study a to their protocol we're could suicidal COVID-XX this better summary, bipolar that, and with lead This if in with in us study depression a now X commercial with application NDA sub-acute if areas. on behavior. focused a studies, patient change commercial NRX-XXX. In bipolar for delivered we care
results. opportunities high populations our see With unmet and compounds of for also I will disease turn brief to other overview over that, We needs. a Ira both to with leverage it in financial areas
